Celadon Pharmaceuticals PLC (CEL) — Cash Flow-to-Debt Ratio
Latest as of June 2024:
-0.21x
Celadon Pharmaceuticals PLC (CEL) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2024, meaning its operating cash flow of GBX-1.29 Million could theoretically repay 0% of its total liabilities (GBX6.01 Million) in one year. See CEL FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.21x
Operating CF / Total Liabilities
Operating Cash Flow
GBX-1.29 Million
GBX
Total Liabilities
GBX6.01 Million
GBX
Data as of
Jun 2024
Most recent filing
Celadon Pharmaceuticals PLC Cash Flow-to-Debt Ratio (2019–2023)
Historical debt coverage capacity for Celadon Pharmaceuticals PLC across 5 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Celadon Pharmaceuticals PLC.
Annual Cash Flow-to-Debt Ratio for Celadon Pharmaceuticals PLC (2019–2023)
Year-by-year debt coverage analysis for Celadon Pharmaceuticals PLC.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.99x | GBX-5.97 Million | GBX6.04 Million | ▼ -0.7% |
| 2022 | -0.98x | GBX-6.10 Million | GBX6.21 Million | ▲ +93.8% |
| 2021 | -15.96x | GBX-3.15 Million | GBX197.23K | ▼ -77099.1% |
| 2020 | -0.02x | GBX-77.57K | GBX3.75 Million | ▼ -2815.9% |
| 2019 | 0.00x | GBX1.98K | GBX2.60 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.